Search Results
Apr 22, 2026, 09:53 ET Hyundai Most Awarded Automaker on the 2026 Best Hybrid and Electric Cars List by U.S. News and World Report
to 335 miles of EPA-estimated driving range. The IONIQ 9 is assembled at the new Hyundai Motor Group Metaplant in Georgia, alongside the IONIQ 5iii."Customers feel stretched every time they fill up at the pump, and there are more electric and hybrid options than ever. The 2026 Best Hybrid
More news about: Hyundai Motor America
Apr 22, 2026, 09:41 ET Einride and Legato Merger Corp. III Announce Public Filing of Registration Statement on Form F-4
[email protected] Merger Corp. IIIEric RosenfeldChief SPAC OfficerLegato Merger Corp. III[email protected] This
More news about: Einride
Apr 22, 2026, 09:34 ET Einride and Legato Merger Corp. III Announce Public Filing of Registration Statement on Form F-4
[email protected] Merger Corp. IIIEric RosenfeldChief SPAC OfficerLegato Merger Corp. III[email protected] This
More news about: Einride
Apr 22, 2026, 09:30 ET 5WPR Publishes the Cannabis Communications Gap Report, Documenting Why a $38.5 Billion Industry Operates with the Weakest Communications Infrastructure in American Business
President Trump's December 18, 2025 executive order directing the Department of Justice to complete the rescheduling of cannabis from Schedule I to Schedule III is the most significant federal cannabis policy development in more than fifty years. The final rule, expected in the first half of 2026, will eliminate
More news about: 5W Public Relations
Apr 22, 2026, 09:00 ET Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of May 22, 2026 in Atara Biotherapeutics, Inc. Lawsuit - ATRA
ALLELE study, made it unlikely that the FDA would approve the tabelecleucel BLA; (ii) accordingly, tabelecleucel's regulatory prospects were overstated; (iii) the aforementioned manufacturing issues also subjected Atara to a heightened risk of regulatory scrutiny, as well as jeopardized its ongoing clinical
More news about: Levi & Korsinsky, LLP
Apr 22, 2026, 08:30 ET Chronic Inflammatory Dermatoses: Designing Trials for Late-Stage Success, Upcoming Webinar Hosted by Xtalks
improvements in patient experience. In this webinar, the featured speaker will outline a strategic framework for designing Phase II and Phase III trials positioned for regulatory, clinical and commercial success in chronic dermatoses. The speaker will discuss how to move beyond short-term response
More news about: Xtalks
Apr 22, 2026, 08:17 ET YY Group (NASDAQ: YYGH) Unveils Scalable AI Training Data Strategy to Power Next-Generation Robotics and Artificial Intelligence
hospitality and workforce markets in Southeast Asia, Hong Kong and other markets in which the Company operates (ii) capital and credit market volatility, (iii) local and global economic conditions, (iv) our anticipated growth strategies, (v) governmental approvals and regulations, (vi) our future business development,
More news about: YY Group Holding Limited
Apr 22, 2026, 08:06 ET LAKE DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Lakeland Industries (LAKE) Investors of Securities Class Action Deadline on April 24, 2026
these businesses on Lakeland's financial results, as well as the overall strength and quality of Pacific Helmets' and Jolly's respective operations; (iii) Lakeland's business and financial results were significantly deteriorating because of, inter alia, tariff-related headwinds and timing, certification
More news about: Faruqi & Faruqi, LLP
Apr 22, 2026, 08:05 ET IMAAVY® (nipocalimab-aahu) shows over two years of sustained disease control in a broad population with generalized myasthenia gravis (gMG)
https://doi.org/10.1007/s13760-022-02162-1iii Antozzi, C et al., Long-term Safety and Efficacy of Nipocalimab: Approximately 2 Years Follow-Up Results from the Open-Label Extension Phase of Vivacity-MG3
More news about: Johnson & Johnson
Apr 22, 2026, 08:00 ET RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical Studies - New Data Presented at AACR 2026
nausea and vomiting. RHB-102 is partnered with Hyloris Pharmaceuticals (EBR: HYL) for worldwide development and commercialization outside North America; (iii) RHB-204, a next-generation optimized formulation of RHB-104, with a planned Phase 2 study for Crohn's disease (based on RHB-104's positive Phase
More news about: RedHill Biopharma Ltd.
Apr 22, 2026, 08:00 ET Contango Announces $9.0 Million Cash Distribution from the Peak Gold JV and Update on 2026 Exploration Plans
patented mining claims located in the Willow Mining District about 75 miles north of Anchorage, Alaska, from the underlying owner, Alaska Hardrock Inc., (iii) mineral rights to approximately 145,000 acres of State of Alaska mining claims, and (iv) mineral rights to approximately 11,700 acres of State of Alaska
More news about: Contango Silver & Gold Inc.
Apr 22, 2026, 07:55 ET SCENTRE GROUP ANNOUNCES CASH TENDER OFFER FOR ANY AND ALL OF ITS OUTSTANDING SUBORDINATED NOTES
reserves the right, subject to applicable law, to (i) waive any and all conditions to the Tender Offer, (ii) extend or terminate the Tender Offer, or (iii) otherwise amend the Tender Offer in any respect.Dealer Managers and Tender and Information AgentThe Offeror has appointed Merrill
More news about: Scentre Group
Apr 22, 2026, 06:15 ET Taylor Morrison Reports First Quarter 2026 Results
information relating to: (i) adjusted net income and adjusted earnings per common share, (ii) adjusted income before income taxes and related margin, (iii) adjusted home closings gross margin, (iv) EBITDA and adjusted EBITDA and (v) net homebuilding debt to capitalization ratio.Adjusted net income,
More news about: Taylor Morrison
Apr 22, 2026, 02:50 ET Samsung Biologics Reports First Quarter 2026 Financial Results
Rockville, Maryland, U.S., Samsung Biologics holds a total global manufacturing capacity of 845,000 liters. The company has also secured land for Bio Campus III, laying the groundwork for future capacity expansion to support next-generation therapies and emerging modalities.Samsung Biologics' global manufacturing
More news about: Samsung Biologics
Apr 21, 2026, 23:08 ET Dayspring Pharma Announces Phase II Trial of CG2001 Foam Met Primary Endpoint in Chinese Adult Men with AGA
University People's Hospital, the 30-week trial was designed to evaluate the efficacy of CG2001 and identify the recommended dosing regimen for Phase III development.Key FindingsAll CG2001 treatment groups demonstrated a markedly superior improvement trend compared to the placebo
More news about: Dayspring Pharma
Apr 21, 2026, 22:00 ET 邁威生物靶向Nectin-4 ADC（9MW2821）治療宮頸癌的病例報告登上《新英格蘭醫學雜誌》
疾病，涉及腫瘤、自身免疫、骨疾病、眼科、血液、心血管等治療領域，憑借國際領先的特色技術平台和研發創新能力，建立了豐富且具有競爭力的管線。現有 15 個處於臨床前、臨床或上市階段的重點品種，包括 11 個創新品種和 4 個生物類似藥，其中 4 個品種上市，1 個品種處於上市審評中，2 個品種處於 III 期關鍵註冊臨床階段。並獨立承擔 1 項國家「重大新藥創製」重大科技專項、2 項國家重點研發計劃和多個省市級科技創新項目。邁威生物以創新為本，注重產業轉化，符合中國 NMPA、美國 FDA、歐盟 EMA GMP標準的抗體和重組蛋白藥物產業化基地已在江蘇泰州投入使用，並已通過歐盟 QP 審計，位於上海金山和江蘇泰州的大規模商業化生產基地正在建設中。欲瞭解更多信息，請訪問：
More news about: 邁威生物
Apr 21, 2026, 22:00 ET Case Report of Mabwell's Nectin-4 targeting ADC (9MW2821) in Cervical Cancer Published in The New England Journal of Medicine
benefits for oncology patients.9MW2821 is the world's first Nectin-4 ADC candidate to enter Phase III clinical trials for cervical cancer. Currently, enrollment for the monotherapy Phase III trial has been completed. Interim analysis is expected to be conducted and pre-NDA
More news about: Mabwell
Apr 21, 2026, 22:00 ET Total Investment of Approx. USD 8.5 Million in Malaria and NTD R&D Projects With Partners Including MMV, GSK, Tanabe Pharma, Eisai and DNDi
StageClinical Phase IIIAwarded Amount
More news about: GHIT Fund
Apr 21, 2026, 22:00 ET Total Investment of Approx. USD 8.5 Million in Malaria and NTD R&D Projects With Partners Including MMV, GSK, Tanabe Pharma, Eisai and DNDi
StageClinical Phase IIIAwarded Amount
More news about: GHIT Fund
Apr 21, 2026, 20:53 ET Kelun-Biotech Announces Three Clinical Study Results Selected for Oral Presentations at 2026 ASCO Annual Meeting
treatment for PD-L1-positive advanced non-small cell lung cancer (NSCLC): Results from the randomized, controlled phase III OptiTROP-Lung05 studyPresentation Type: OralAbstract Number: 8506Session Date and Time: May 29,
More news about: Kelun-Biotech
Apr 21, 2026, 20:00 ET Innovent to Present New Clinical Data of IBI363（PD-1/IL-2α-biased bispecific fusion protein） at the 2026 ASCO Annual Meeting
Sintilimab Versus Sorafenib in the First-line Treatment of Advanced Hepatocellular Carcinoma (aHCC): A Randomized, Open-label, Controlled, Multicenter Phase III Clinical Study Abstract Number: 4148Session Type: PosterSession Title: Gastrointestinal Cancer—Gastroesophageal, Pancreatic,
More news about: Innovent Biologics
Apr 21, 2026, 18:50 ET /U P D A T E -- Nuvation Bio Inc./
disease-free survival as determined by investigator, and the primary completion date is estimated to be in 2030. Nuvation Bio is also sponsoring TRUST-III (
More news about: Nuvation Bio Inc.
Apr 21, 2026, 18:05 ET MEDP INVESTOR DEADLINE: Medpace Holdings Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
book-to-bill ratio for fourth quarter 2025; (ii) Medpace knew or recklessly disregarded the impact that cancellations have on Medpace's book-to-bill ratio; (iii) Medpace frequently claimed that the projection of a 1.15 book-to-bill ratio for fourth quarter 2025 was reasonable and achievable and that cancellations
More news about: Robbins Geller Rudman & Dowd LLP
Apr 21, 2026, 17:55 ET 8 Greenberg Traurig Attorneys to Speak at eMerge Americas Conference
John D. Owens, III, Miami Corporate shareholderDate and time: April 23, 1:30-2 p.m.Topic: The Mainstreaming of Secondaries: The Role of Secondaries
More news about: Greenberg Traurig, LLP
Apr 21, 2026, 16:25 ET WesBanco Announces First Quarter 2026 Financial Results
consolidated and bank-level regulatory capital ratios are well above the applicable "well-capitalized" standards promulgated by bank regulators and the BASEL III capital standards. At March 31, 2026, Tier I leverage was 9.63%, Tier I risk-based capital ratio was 11.72%, common equity Tier 1 capital ratio ("CET
More news about: WesBanco, Inc.